Hepatic fibrosis of any origin in a large population of type 2 diabetes patients

Author(s):  
Carlo b. Giorda ◽  
Roberta Picariello ◽  
Barbara Tartaglino ◽  
Elisa Nada ◽  
Cristina Linzalata ◽  
...  
2012 ◽  
Vol 8 (4S_Part_4) ◽  
pp. P136-P137
Author(s):  
Elizabeth Mayeda ◽  
Andrew Karter ◽  
Elbert Huang ◽  
Howard Moffet ◽  
Priya John ◽  
...  

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1616-P ◽  
Author(s):  
SANDRINE I. SAMSON ◽  
WEI-NCHIH LEE ◽  
THOMAS QUISEL ◽  
LUCA FOSCHINI ◽  
JAN LISKA ◽  
...  

2018 ◽  
Vol 135 ◽  
pp. 65-72 ◽  
Author(s):  
Carlo Bruno Giorda ◽  
Gabriele Forlani ◽  
Roberta Manti ◽  
Arianna Mazzotti ◽  
Salvatore De Cosmo ◽  
...  

2019 ◽  
Author(s):  
Marius Kincius ◽  
Patasius Ausvydas ◽  
Linkeviciute-Ulinskiene Donata ◽  
Rimantas Stukas ◽  
Zabuliene Lina ◽  
...  

Abstract Background: The aim of this study was to determine whether type 2 diabetes mellitus and treatment with metformin is associated with prostate cancer risk. Methods: Male patients with diagnosis of type 2 diabetes during the period of 2000 – 2016 were identified in the National Health Insurance Fund database. The prostate cancer cases were identified by pooling these records from the national Cancer Registry. The calculation of prostate cancer stardardized incidence ratios (SIRs) was composed as a ratio of observed number of cancer case in people with diagnosis of diabetes to the expected number of cancer cases in the underlying general population. Results: Overall, 64,000 males diagnosed with diabetes in Lithuania between 2000 and 2016 were included in the final cohort. 2,754 prostate cancers were observed versus 3,111.26 expected within the period of observation entailing an SIR of 0.89 (95% CI: 0.85–0.92). Significantly lower risk of prostate cancer was found in diabetes patients in all age groups, there were no differences in prostate cancer risk by time since diagnosis of diabetes. Significantly lower risk of prostate cancer also was found in both metformin users and never-users’ groups, with higher risk reduction in metformin users (SIR 0.71, 95% CI: 0.68–0.75) than in diabetes patients never-users (SIR 0.88, 95% CI: 0.80–0.96). Conclusions: In this large population-based study we found a significantly decreased risk of prostate cancer among men with diabetes and metformin users. However, the risk of prostate cancer showed no clear trend with diabetes duration and cumulative metformin dose.


2019 ◽  
Vol 56 (11) ◽  
pp. 1199-1207 ◽  
Author(s):  
Asieh Mansour ◽  
Mohammad Reza Mohajeri-Tehrani ◽  
Majid Samadi ◽  
Hadis Gerami ◽  
Mostafa Qorbani ◽  
...  

2020 ◽  
Vol 11 (1) ◽  
pp. 7-10
Author(s):  
Khadiza Begum ◽  
Fahmida Islam ◽  
Farjana Aktar ◽  
Murshida Aziz ◽  
Tohfa E Ayub Tahiya

Background: In recent times much is talked about of serum ferritin, an acute phase reactant a marker of iron stores in the body and its association with diabetes mellitus. Studies implicate that increased body iron stores and subclinical hemochromatosis has been associated with the development of glucose intolerance, type 2 diabetes and its micro as well as macrovascular complications. Material & Methods: This study was carried out to examine and to observe for any relationship between serum ferritin with Type 2 diabetes mellitus. Our study populations were included 163. Among them 81 type 2 diabetes patients as a case (M=49,F=32, mean 44.68 age in years)and 82 normal healthy individual as a control ( M=35, F=47 , mean 34.71 in years). Results: Majority were healthy outpatients who had come for regular checkup and were matched with controls. Serum ferritin and FBS were estimated and other investigations. Results showed that although Serum ferritin was in the normal range value it was increased in type 2 diabetes patients than in controls and was statistically significant, we did get a positive correlation with duration of diabetes. It can be concluded that there were positive associations between serum ferritin and FBG, age, sex among study groups. Conclusion: In conclusion our study shows that there is significant correlation between increased serum ferritin in diabetes compared to individuals with normal blood sugars in this part and hyper ferritinemia may be one of the causes for development of insulin resistance before overt diabetes. Anwer Khan Modern Medical College Journal Vol. 11, No. 1: Jan 2020, P 7-10


Sign in / Sign up

Export Citation Format

Share Document